“Pyrotinib, Trastuzumab, and Chemotherapy: Higher Pathological Complete Response Rates in HER2-Positive Breast Cancer Neoadjuvant Therapy”

https://pubmed.ncbi.nlm.nih.gov/38114991

The combination of pyrotinib, trastuzumab, and chemotherapy as neoadjuvant therapy for HER2-positive breast cancer results in higher pathological complete response rates compared to trastuzumab and chemotherapy alone, with manageable side effects.